Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE1317.7546.2 (+3.63 %)

PREV CLOSE ( ) 1271.55

OPEN PRICE ( ) 1288.90

BID PRICE (QTY) 1317.35 (2)

OFFER PRICE (QTY) 1318.45 (58)

VOLUME 78757

TODAY'S LOW / HIGH ( )1285.05 1349.70

52 WK LOW / HIGH ( )987.05 2149.9

NSE1317.0044.8 (+3.52 %)

PREV CLOSE( ) 1272.20

OPEN PRICE ( ) 1284.00

BID PRICE (QTY) 1317.00 (75)

OFFER PRICE (QTY) 1317.80 (1)

VOLUME 1081916

TODAY'S LOW / HIGH( ) 1282.60 1349.90

52 WK LOW / HIGH ( )987 2150.4

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984

Management Info

Sudhir Vaid - Chairman Sudhir Vaid - Managing Director

Registered Office

Address 1482-1486 ,Trasad Road,Dholka,
Ahmedabad Dist,
Gujarat-382225

Phone 02714-222604 / 398200

Email complianceofficer@concordbiotech.com

Website www.concordbiotech.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

10Jun Concord Biotech gets USFDA’s nod for T
Concord Biotech has received approval from the U.S. Food and Drug Admini..

10Jun Concord Biotech zooms after getting US
Concord Biotech is currently trading at Rs. 1330.50, up by 58.95 points..

10Jun Concord Biotech informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

03Jun Concord Biotech gets USFDA nod for Myc
Concord Biotech has received approval from the U.S. Food and Drug Admini..

03Jun Concord Biotech soars on getting USFDA
Concord Biotech is currently trading at Rs. 1231.00, up by 64.20 points..

Financials

Rs. in Millions

	QTR Mar 26	ANNUAL 26
Net Profit	900.22	2632.67
Gross Profit	1183.78	3514.32
Operating Profit	1379.23	4292.66
Net Sales	3258.92	10550.71

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE) 3177.00 (0.74%)	M.Cap ( in Cr)7304.05
Fredun Pharma (BSE) 2325.05 (0.60%)	M.Cap ( in Cr)1297.00
Jenburkt Pharma (BSE) 1172.60 (0.81%)	M.Cap ( in Cr)521.21
Ishita Drugs & Inds. (BSE) 79.65 (7.45%)	M.Cap ( in Cr)23.86
Zim Laboratories (BSE) 113.70 (4.70%)	M.Cap ( in Cr)608.85

Shareholding Pattern

	PROMOTERS	44.08%
	NON-INSTITUTION	38.9%
	MUTUAL FUNDS/UTI	4.3%
	FI/BANKS/INSURANCE	3.89%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	2.95
LIC MF Healthcare F...	2.59
SBI Healthcare Opp ...	2.39
Baroda BNP Paribas ...	2.13
Baroda BNP Paribas ...	2.01
Baroda BNP Paribas ...	1.71
Invesco India Manuf...	1.58

Risk Disclosures on Derivatives

Smart Quotes

CONCORD BIOTECH LTD.